Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 CCR5 5件: Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Viral protein interaction with cytokine and cytokine receptor, Toxoplasmosis, Viral carcinogenesis D06670 Maraviroc 2件: 46, 84
2 CCR5 5件: Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Viral protein interaction with cytokine and cytokine receptor, Toxoplasmosis, Viral carcinogenesis D09878 Cenicriviroc 1件: 94
3 MAPK14 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod 2件: 113, 222
4 MAPK14 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod 1件: 8
5 ALOX5 1件: Toxoplasmosis D00414 Zileuton 3件: 85, 160, 164
6 ALOX5 1件: Toxoplasmosis D01773 Oxatomide 1件: 113
7 IFNG 3件: Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D04242 Fontolizumab 1件: 46
8 IFNG 3件: Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D11120 Emapalumab 3件: 49, 65, 107
9 IFNGR1 2件: Toxoplasmosis, Tuberculosis D00747 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326
10 IFNGR2 2件: Toxoplasmosis, Tuberculosis D00747 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326
11 IL10 4件: Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Toxoplasmosis, Tuberculosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
12 IL12A 3件: Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D09214 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
13 IL12B 3件: Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D09214 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
14 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D09959 Ruxolitinib 3件: 60, 65, 228
15 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
16 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10308 Baricitinib 13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
17 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10653 Peficitinib 1件: 46
18 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10871 Filgotinib 6件: 46, 53, 96, 97, 222, 271
19 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10944 Itacitinib 4件: 46, 51, 97, 228
20 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10994 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271
21 JAK1 3件: Toxoplasmosis, Tuberculosis, Viral carcinogenesis D11400 Abrocitinib 1件: 84
22 JAK2 2件: Toxoplasmosis, Tuberculosis D09959 Ruxolitinib 3件: 60, 65, 228
23 JAK2 2件: Toxoplasmosis, Tuberculosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
24 JAK2 2件: Toxoplasmosis, Tuberculosis D10308 Baricitinib 13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
25 JAK2 2件: Toxoplasmosis, Tuberculosis D10653 Peficitinib 1件: 46
26 NFKB1 5件: Yersinia infection, Toxoplasmosis, Tuberculosis, Transcriptional misregulation in cancer, Viral carcinogenesis D01146 Iguratimod 5件: 46, 51, 53, 271, 300
27 MAPK11 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod 2件: 113, 222
28 MAPK11 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod 1件: 8
29 MAPK13 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod 2件: 113, 222
30 MAPK13 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod 1件: 8
31 BCL2 2件: Toxoplasmosis, Tuberculosis D10679 Venetoclax 1件: 28
32 RELA 5件: Yersinia infection, Toxoplasmosis, Tuberculosis, Transcriptional misregulation in cancer, Viral carcinogenesis D12181 Edasalonexent 1件: 113
33 MAPK12 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod 2件: 113, 222
34 MAPK12 4件: VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod 1件: 8
35 TGFB1 2件: Toxoplasmosis, Tuberculosis D09620 Fresolimumab 3件: 51, 85, 222
36 TGFB2 2件: Toxoplasmosis, Tuberculosis D09620 Fresolimumab 3件: 51, 85, 222
37 TGFB3 2件: Toxoplasmosis, Tuberculosis D09620 Fresolimumab 3件: 51, 85, 222
38 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D00742 Etanercept 16件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285
39 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D00754 Thalidomide 20件: 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
40 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
41 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D02597 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271
42 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D02598 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
43 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D03441 Certolizumab pegol 8件: 37, 46, 49, 96, 97, 107, 226, 271
44 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D04358 Golimumab 8件: 46, 56, 84, 96, 97, 107, 270, 271
45 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D04687 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331
46 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D05393 Pegsunercept 1件: 46
47 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D08976 Pomalidomide 5件: 28, 51, 85, 227, 331
48 TNF 6件: Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D09944 Ozoralizumab 1件: 46
49 TYK2 1件: Toxoplasmosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
50 TYK2 1件: Toxoplasmosis D11817 Deucravacitinib 3件: 49, 96, 97
51 CASP9 4件: VEGF signaling pathway, Toxoplasmosis, Tuberculosis, Viral myocarditis D11195 Rimiducid 6件: 19, 60, 65, 284, 285, 326
52 CD40 3件: Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis D11357 Bleselumab 1件: 222
53 CD40 3件: Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis D11597 Ravagalimab 2件: 53, 97
54 CD40 3件: Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis D11610 Iscalimab 2件: 49, 53
55 CD40LG 2件: Toxoplasmosis, Viral myocarditis D06193 Toralizumab 1件: 63